Hemophilia of Georgia Board of Directors Names Maria Pérez Manahan as CEO
The Hemophilia of Georgia Board of Directors announced on March 9, 2015 that it has appointed Maria Manahan as Chief Executive Officer. Maria will assume leadership of Hemophilia of Georgia on April 1, 2015 from current CEO, Trish Dominic, who is retiring after 30 years at the organization’s helm. During Ms. Dominic’s tenure, Hemophilia of Georgia has grown to become one of the leading hemophilia organizations in the world.
Board Member Neca Smith, Chair of the HoG CEO Search Committee, said that following an extensive nationwide search conducted by Washington, DC based executive search firm Vetted Solutions, the decision to appoint Maria Manahan was unanimous. Maria joined Hemophilia of Georgia in September 2000 and currently serves as Vice President of Finance & Operations for the organization. In this role she has managed pharmacy operations, the business department and the agency’s finances while contributing as a member of the senior management team.
Trish Dominic said, “I have so enjoyed working with Maria for the past 15 years and I think she will do an outstanding job.”
Maria has a Master of Science degree, Policy Studies, Nonprofit Management from Georgia State University and a Bachelor of Science in Urban Studies from Georgia State University. Maria is a Board Member of the Hemophilia Alliance (as well as an officer), on the board of the Campbell-Stone Apartments, and the 340B Advisory Board of the Hemophilia Treatment Center Pharmacy at the University of North Carolina, Chapel Hill. Prior to joining Hemophilia of Georgia, Maria was Director of Assisted Living and Alzheimer’s Programs at Campbell-Stone Apartments.
Maria was born in Cuba and speaks fluent Spanish. She is married to a Georgia native, Russell, and they have two adult children, Natalie and Nathan.
“I am very excited and honored to be the next CEO of Hemophilia of Georgia. I look forward to working closely with the bleeding disorder community as we pursue opportunities together to improve care and treatment and to fund research for a cure.”